Avid Bioservices Inc (CDMO)

[biopharm]

PR 8-25-05: PPHM Licenses Anti-PSMA VTA to MEDX

“Peregrine Pharmaceuticals Enters Into Licensing Agreement With Medarex to Develop Vascular Targeting Agents - Agreement Represents the Third Licensing Collaboration Under Peregrine's VTA Platform Technology”
http://ir.peregrineinc.com/phoenix.zhtml?c=74236&p=irol-newsArticle&ID=749491
TUSTIN, CA, Aug 25 2005: Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a broad portfolio of products under development directed towards the treatment of cancer, viruses and other diseases, announced today that it has entered into a license agreement with Medarex, Inc. (Nasdaq: MEDX). Under the agreement, the company licensed to Medarex certain intellectual property rights under its broad Vascular Targeting Agent technology platform. This license allows Medarex to develop and commercialize their anti-PSMA monoclonal antibody conjugated to therapeutic agents and use the resulting conjugate for the treatment of a wide range of solid tumors.

Under the terms of the agreement, Peregrine Pharmaceuticals will receive an upfront payment and annual maintenance fees and may receive future payments based on the achievement of clinical milestones and a royalty on net sales if a product developed under the agreement is approved under the FDA. Further financial details were not disclosed.
....
....
..

There is more the current BODs are not telling us...

Terry, great find on the Medarex Anti-PSMA AACR abstract #1171 (4-2-06), which relates to the 8-2005 licensing by Medarex of Peregrine’s Anti-PSMA technology for the treatment of solid tumors. Gotta love the Medarex conclusion:

…Treatment of established LNCaP tumor xenografts with anti-PSMA conjugate at a single dose of 0.3 umol/kg resulted in complete tumor regression with no associated weight loss. Further definition of the therapeutic window has revealed significant therapeutic effects at very well tolerated doses. Human clinical testing for the treatment of drug-resistant prostate cancer is planned.”

= = = = = = = = =
4-4-06 AACR #1171: PPHM/MEDAREX’s Anti-PSMA

AACR/4-2-06 abstract #1171 “Human Antibody Conjugates Of DNA Minor Groove-Binding Alkylating Agents wth Single Dose Efficacy in Xenograft Models Which Retain Activity in Drug Resistant Cells” by Medarex’ David J. King relates to the 8-2005 licensing by Medarex of Peregrine’s Anti-PSMA technology for the treatment of solid tumors. Peregrine received an upfront payment and annual maint. fees, and may receive future payments based on the achievement of clinical milestones and a royalty on net sales if approved by FDA. http://www.medarex.com/Strategy/Partners.htm

....
....
....

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=10009281

The effector functions present within the IP assets of Peregrine/Avid ...must be worth much than all thought especially when the effector functions of other IP crosses with the IP of PS Targeting. Was BMY interested in Medarex because Peregrine had signed on with Medarex? Very possibly yes and on top of it all, did the new BODs ever know about half of the past ...

This article reports the design, synthesis, and evaluation of a novel class of molecules of intermediate size (approximately 7000 Da), which possess both the targeting and effector functions of antibodies. These compounds—called synthetic antibody mimics targeting prostate cancer (SyAM-Ps)—bind simultaneously to prostate-specific membrane antigen and Fc gamma receptor I, thus eliciting highly selective cancer cell phagocytosis. SyAMs have the potential to combine the advantages of both small-molecule and biologic therapies, and may address many drawbacks associated with available treatments for cancer and other diseases.

https://www.ncbi.nlm.nih.gov/m/pubmed/25514603/